SCHEMBL13739719

SCHEMBL13739719

O=C(CN1CCCC1)c1cnn(-c2ccc(Cl)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
MAPT P10636 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
MAP4K4 O95819 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
USP14 P54578 5/20 0.48
USP7 Q93009 1/20 0.48
MAPK1 P28482 2/20 0.47
RECQL P46063 1/20 0.47
DRD4 P21917 2/20 0.46
DRD2 P14416 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GFER P55789 1/20 0.46
HTR2C P28335 1/20 0.45
EIF4A3 P38919 1/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13739264 0.99 USP14 (0.50) NPC1RAB9AMAPTNFKB1NFKB2
SCHEMBL13832641 0.85 KDM4E (0.50) NPC1RAB9AMAPTSMN1; SMN2USP14
SCHEMBL13741212 0.80 MAPT (0.58) NPC1RAB9AMAPTNFKB1NFKB2
SCHEMBL26921192 0.79 ALDH1A1 (0.59) NPC1RAB9AMAPTSMN1; SMN2USP14
SCHEMBL26921088 0.78 ALDH1A1 (0.62) RAB9AMAPTSMN1; SMN2USP14USP7
SCHEMBL16467066 0.76 NPC1 (0.61) NPC1RAB9AMAPTNFKB1NFKB2
SCHEMBL2860260 0.76 ALKBH2 (0.72) NPC1RAB9AMAPTNFKB1NFKB2
Hydrochloric Acid SCHEMBL16467067 0.75 ALKBH2 (0.70) NPC1RAB9AMAPTNFKB1NFKB2
SCHEMBL27940224 0.74 NTSR1 (0.46) NPC1RAB9AMAPTNFKB1NFKB2
SCHEMBL21479799 0.74 SIGMAR1 (0.40) NPC1RAB9ASMN1; SMN2USP14USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12180189-B2 Proteostasis regulators Kineta, Inc. (US) 2024-12-31 US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 US disclosed
US-20200299270-A1 PROTEOSTASIS REGULATORS Kineta, Inc. 2020-09-24 US disclosed
EP-3552664-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2019-10-16 EP disclosed
EP-3552664-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2019-10-16 EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 EP disclosed
EP-2707101-B1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS INC (US) 2019-02-13 EP disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-20170247355-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2017-08-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
US-9556166-B2 Proteostasis regulators PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-01-31 US disclosed
EP-2707101-A1 PROTEOSTASIS REGULATORS Proteostasis Therapeutics, Inc. (US) 2014-03-19 EP disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
US-20120316193-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. 2012-12-13 US disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed
WO-2012154967-A1 PROTEOSTASIS REGULATORS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299270-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 NPC1 1036/4885RAB9A 458/4885MAPT 577/4885
US-20170247355-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 NPC1 1036/4885RAB9A 458/4885MAPT 577/4885
US-12180189-B2 Proteostasis regulators PSMG3, VCP, HSPA5 NPC1 1036/4885RAB9A 458/4885MAPT 577/4885
US-20120316193-A1 PROTEOSTASIS REGULATORS PSMG3, VCP, HSPA5 NPC1 1036/4885RAB9A 458/4885MAPT 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.